236 related articles for article (PubMed ID: 30146241)
1. Combining Mutational Signatures, Clonal Fitness, and Drug Affinity to Define Drug-Specific Resistance Mutations in Cancer.
Kaserer T; Blagg J
Cell Chem Biol; 2018 Nov; 25(11):1359-1371.e2. PubMed ID: 30146241
[TBL] [Abstract][Full Text] [Related]
2. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
Lin YT; Chiang CL; Hung JY; Lee MH; Su WC; Wu SY; Wei YF; Lee KY; Tseng YH; Su J; Chung HP; Lin CB; Ku WH; Chiang TS; Chiu CH; Shih JY
Eur J Cancer; 2021 Oct; 156():1-11. PubMed ID: 34392186
[TBL] [Abstract][Full Text] [Related]
3. Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in
Pailler E; Faugeroux V; Oulhen M; Mezquita L; Laporte M; Honoré A; Lecluse Y; Queffelec P; NgoCamus M; Nicotra C; Remon J; Lacroix L; Planchard D; Friboulet L; Besse B; Farace F
Clin Cancer Res; 2019 Nov; 25(22):6671-6682. PubMed ID: 31439588
[TBL] [Abstract][Full Text] [Related]
4. Resistor: An algorithm for predicting resistance mutations via Pareto optimization over multistate protein design and mutational signatures.
Guerin N; Feichtner A; Stefan E; Kaserer T; Donald BR
Cell Syst; 2022 Oct; 13(10):830-843.e3. PubMed ID: 36265469
[TBL] [Abstract][Full Text] [Related]
5. Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance.
Okada K; Araki M; Sakashita T; Ma B; Kanada R; Yanagitani N; Horiike A; Koike S; Oh-Hara T; Watanabe K; Tamai K; Maemondo M; Nishio M; Ishikawa T; Okuno Y; Fujita N; Katayama R
EBioMedicine; 2019 Mar; 41():105-119. PubMed ID: 30662002
[TBL] [Abstract][Full Text] [Related]
6. INTEGRATING GENETIC AND STRUCTURAL DATA ON HUMAN PROTEIN KINOME IN NETWORK-BASED MODELING OF KINASE SENSITIVITIES AND RESISTANCE TO TARGETED AND PERSONALIZED ANTICANCER DRUGS.
Verkhivker GM
Pac Symp Biocomput; 2016; 21():45-56. PubMed ID: 26776172
[TBL] [Abstract][Full Text] [Related]
7. A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients.
Tiedt R; Degenkolbe E; Furet P; Appleton BA; Wagner S; Schoepfer J; Buck E; Ruddy DA; Monahan JE; Jones MD; Blank J; Haasen D; Drueckes P; Wartmann M; McCarthy C; Sellers WR; Hofmann F
Cancer Res; 2011 Aug; 71(15):5255-64. PubMed ID: 21697284
[TBL] [Abstract][Full Text] [Related]
8. Structure and energy based quantitative missense variant effect analysis provides insights into drug resistance mechanisms of anaplastic lymphoma kinase mutations.
Li J; Huang Y; Wu M; Wu C; Li X; Bao J
Sci Rep; 2018 Jul; 8(1):10664. PubMed ID: 30006516
[TBL] [Abstract][Full Text] [Related]
9. ERK Mutations and Amplification Confer Resistance to ERK-Inhibitor Therapy.
Jaiswal BS; Durinck S; Stawiski EW; Yin J; Wang W; Lin E; Moffat J; Martin SE; Modrusan Z; Seshagiri S
Clin Cancer Res; 2018 Aug; 24(16):4044-4055. PubMed ID: 29760222
[No Abstract] [Full Text] [Related]
10. [The importance of mutational status in prognosis and therapy of GIST].
Comandone A; Boglione A
Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
[TBL] [Abstract][Full Text] [Related]
11. Enigmas in tumor resistance to kinase inhibitors and calculation of the drug resistance index for cancer (DRIC).
Smith CIE
Semin Cancer Biol; 2017 Aug; 45():36-49. PubMed ID: 27865897
[TBL] [Abstract][Full Text] [Related]
12. Somatic mutation patterns and compound response in cancers.
He N; Kim N; Yoon S
BMB Rep; 2013 Feb; 46(2):97-102. PubMed ID: 23433112
[TBL] [Abstract][Full Text] [Related]
13. Systematic profiling of staralog response to acquired drug resistant kinase gatekeeper mutations in targeted cancer therapy.
Yang Y; Qiu Y; Liu X; Liu Y; Yin Y; Li P
Amino Acids; 2020 Apr; 52(4):511-521. PubMed ID: 32206932
[TBL] [Abstract][Full Text] [Related]
14. Taking advantage of drug resistance, a new approach in the war on cancer.
Wang L; Bernards R
Front Med; 2018 Aug; 12(4):490-495. PubMed ID: 30022460
[TBL] [Abstract][Full Text] [Related]
15. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA.
Murtaza M; Dawson SJ; Tsui DW; Gale D; Forshew T; Piskorz AM; Parkinson C; Chin SF; Kingsbury Z; Wong AS; Marass F; Humphray S; Hadfield J; Bentley D; Chin TM; Brenton JD; Caldas C; Rosenfeld N
Nature; 2013 May; 497(7447):108-12. PubMed ID: 23563269
[TBL] [Abstract][Full Text] [Related]
16. APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas.
Selenica P; Marra A; Choudhury NJ; Gazzo A; Falcon CJ; Patel J; Pei X; Zhu Y; Ng CKY; Curry M; Heller G; Zhang YK; Berger MF; Ladanyi M; Rudin CM; Chandarlapaty S; Lovly CM; Reis-Filho JS; Yu HA
Ann Oncol; 2022 Dec; 33(12):1284-1295. PubMed ID: 36089134
[TBL] [Abstract][Full Text] [Related]
17. Strategies for Overcoming Resistance in Tumours Harboring BRAF Mutations.
Obaid NM; Bedard K; Huang WY
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28282860
[TBL] [Abstract][Full Text] [Related]
18. The Clinical Kinase Index: A Method to Prioritize Understudied Kinases as Drug Targets for the Treatment of Cancer.
Essegian D; Khurana R; Stathias V; Schürer SC
Cell Rep Med; 2020 Oct; 1(7):100128. PubMed ID: 33205077
[TBL] [Abstract][Full Text] [Related]
19. Chemical strategies to overcome resistance against targeted anticancer therapeutics.
Pisa R; Kapoor TM
Nat Chem Biol; 2020 Aug; 16(8):817-825. PubMed ID: 32694636
[TBL] [Abstract][Full Text] [Related]
20. ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy.
Aceves-Luquero CI; Agarwal A; Callejas-Valera JL; Arias-González L; Esparís-Ogando A; del Peso Ovalle L; Bellón-Echeverria I; de la Cruz-Morcillo MA; Galán Moya EM; Moreno Gimeno I; Gómez JC; Deininger MW; Pandiella A; Sánchez Prieto R
PLoS One; 2009 Jul; 4(7):e6124. PubMed ID: 19568437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
